TY - JOUR
T1 - Cancer screening participation in schizophrenic outpatients and the influence of their functional disability on the screening rate
T2 - A cross-sectional study in Japan
AU - Fujiwara, Masaki
AU - Inagaki, Masatoshi
AU - Nakaya, Naoki
AU - Fujimori, Maiko
AU - Higuchi, Yuji
AU - Hayashibara, Chinatsu
AU - So, Ryuhei
AU - Kakeda, Kyoko
AU - Kodama, Masafumi
AU - Uchitomi, Yosuke
AU - Yamada, Norihito
N1 - Funding Information:
Dr Fujiwara reports grants from Okayama Health Foundation, Novartis Pharma, and Research for Promotion of Cancer Control Programs during the conduct of the study; personal fees from Mochida Pharmaceutical Co., Ltd., Eli Lilly Japan Co., Ltd., Sentan Igaku-Sha Ltd., Igaku-shoin Ltd., and Seiwa Shoten, outside the submitted work. Dr Inagaki reports grants from Okayama Health Foundation, Novartis Pharma, and Research for Promotion of Cancer Control Programs during the conduct of the study; personal fees from Mochida Pharmaceutical Co., Ltd., Shionogi & Co., Ltd., Sumitomo Dainip-pon Pharma Co., Ltd., Daiichi-Sankyo Co., Ltd., Meiji Seika Pharma Co. Ltd., Takeda Pharmaceutical Co., Ltd., Nippon Hyoron Sha Co., Ltd., Nanzando Co., Ltd., Seiwa Shoten Co., Ltd., Igaku-shoin Ltd., and Technomics, Inc. outside the submitted work. Dr Fujimori reports grants from Research for Promotion of Cancer Control Programs during the conduct of the study; personal fees from Mochida Pharmaceutical Co., Ltd., Igaku-Shoin Ltd., Chugai-Iga-kusha, Nankodo Co., Ltd., and Kongo-Shuppan, outside the submitted work. Ms Hayashibara reports grants from Okayama Health Foundation, Novartis Pharma, and Research for Promotion of Cancer Control Programs during the conduct of the study. Dr So reports personal fees from Kagakuhyronsha Co., Ltd., Medical Review Co., Ltd., and Otsuka Pharmaceutical Co., Ltd., outside the submitted work. Dr Kakeda reports personal fees from Mochida Pharmaceutical Co., Ltd., outside the submitted work. Dr Kodama reports personal fees from Janssen Pharmaceutical Co., Ltd., Otsuka Pharmaceutical Co., Ltd., MSD Co., Ltd., Eisai Co., Ltd., Yoshitomiyakuhin Co., Ltd., and Eli Lilly Japan Co., Ltd., outside the submitted work. Dr Uchitomi reports grants and personal fees from Research for Promotion of Cancer Control Programs during the conduct of the study; personal fees from Mochida Pharmaceutical Co., Ltd. and Eisai Pharmaceutical Co., Ltd., and other support from QOL Co., Ltd., outside the submitted work; and annual fees under 500 000 JPY from an undisclosed company. Dr Yamada reports grants from Okayama Health Foundation, Novartis Pharma, and Research for Promotion of Cancer Control Programs during the conduct of the study; grants from Daiichi Sankyo Co., Ltd., Eisai Co., Ltd., Otsuka Pharmaceutical Co., Ltd., Astellas Pharma Inc., MSD. K.K., and Pfizer Inc, personal fees from Otsuka Pharmaceutical Co., Ltd., MSD, K.K., Meiji Seika Pharma Co., Ltd., Janssen Pharmaceutical K.K., Eli Lilly Japan K.K., Kyowa Hakko Kirin Co., Ltd., Hisamitsu Pharmaceutical Co., Inc, Sumitomo Dai-nippon Pharma Co., Ltd., and Mochida Pharmaceutical Co., Ltd., outside the submitted work. The other authors declare no conflicts of interest.
Funding Information:
We thank Ms Kimiko Takaoka who was a research assistant and helped conduct the questionnaire survey, Ms Megumi Miki who assisted with data management, Ms Shoko Yoshimoto who supported our entire study with logistics assistance, and all the outpatient service staff at the Okayama Psychiatric Medical Center. This study was supported by the Okayama Health Foundation, Novartis Pharma Research Grants, and Research for Promotion of Cancer Control Programs (H26-political-general-002). These sources had no further role in study design, in the collection, analysis and interpretation of data, in the writing of the report, or in the decision to submit the paper for publication.
Publisher Copyright:
© 2017 The Authors. Psychiatry and Clinical Neurosciences © 2017 Japanese Society of Psychiatry and Neurology
PY - 2017/12
Y1 - 2017/12
N2 - Aim: The influence of schizophrenic patients’ functional disability on cancer screening participation worldwide is unclear. There are few findings on the disparities in schizophrenic patients’ participation in cancer screening programs in Asia. The aim of this study was to investigate the screening rate and the associations between screening and symptom severity/functional disability in patients with schizophrenia. Methods: This cross-sectional study was conducted in a psychiatric hospital outpatient clinic in Japan. We recruited schizophrenic patients meeting the national program criteria for cancer screening for colorectal, gastric, lung, breast, and cervical cancer (n = 224, 223, 224, 110, and 175, respectively). Receipt of cancer screenings was assessed using a self-report questionnaire. Scores on the modified Global Assessment of Functioning (mGAF) were evaluated by participants’ primary psychiatrists. Results: Rates of cancer screenings were as follows: 24.1% for colorectal, 21.5% for gastric, 30.8% for lung, 25.5% for breast, and 19.4% for cervical cancer. A multivariable logistic analysis showed that a 1-point increase in severity/disability (100 minus mGAF score) was associated with significantly lower odds ratios (OR) for receipt of cancer screenings, except for breast cancer (OR, 0.95, 95% confidence interval [CI], 0.93–0.98 for colorectal; OR, 0.96, 95%CI, 0.93–0.98 for gastric; OR, 0.95, 95%CI, 0.93–0.97 for lung; OR, 0.97, 95%CI, 0.94–1.00 for breast; and OR, 0.95, 95%CI, 0.92–0.98 for cervical cancer). Conclusion: The findings demonstrated low rates of cancer screenings in schizophrenic patients in Japan. Our study suggests the need to encourage attendance at cancer screenings, especially in schizophrenic patients with severe symptoms/functional disability.
AB - Aim: The influence of schizophrenic patients’ functional disability on cancer screening participation worldwide is unclear. There are few findings on the disparities in schizophrenic patients’ participation in cancer screening programs in Asia. The aim of this study was to investigate the screening rate and the associations between screening and symptom severity/functional disability in patients with schizophrenia. Methods: This cross-sectional study was conducted in a psychiatric hospital outpatient clinic in Japan. We recruited schizophrenic patients meeting the national program criteria for cancer screening for colorectal, gastric, lung, breast, and cervical cancer (n = 224, 223, 224, 110, and 175, respectively). Receipt of cancer screenings was assessed using a self-report questionnaire. Scores on the modified Global Assessment of Functioning (mGAF) were evaluated by participants’ primary psychiatrists. Results: Rates of cancer screenings were as follows: 24.1% for colorectal, 21.5% for gastric, 30.8% for lung, 25.5% for breast, and 19.4% for cervical cancer. A multivariable logistic analysis showed that a 1-point increase in severity/disability (100 minus mGAF score) was associated with significantly lower odds ratios (OR) for receipt of cancer screenings, except for breast cancer (OR, 0.95, 95% confidence interval [CI], 0.93–0.98 for colorectal; OR, 0.96, 95%CI, 0.93–0.98 for gastric; OR, 0.95, 95%CI, 0.93–0.97 for lung; OR, 0.97, 95%CI, 0.94–1.00 for breast; and OR, 0.95, 95%CI, 0.92–0.98 for cervical cancer). Conclusion: The findings demonstrated low rates of cancer screenings in schizophrenic patients in Japan. Our study suggests the need to encourage attendance at cancer screenings, especially in schizophrenic patients with severe symptoms/functional disability.
KW - cancer screening
KW - disparity
KW - mental illness
KW - prevention
KW - schizophrenia
UR - http://www.scopus.com/inward/record.url?scp=85037327569&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85037327569&partnerID=8YFLogxK
U2 - 10.1111/pcn.12554
DO - 10.1111/pcn.12554
M3 - Article
C2 - 28875514
AN - SCOPUS:85037327569
SN - 1323-1316
VL - 71
SP - 813
EP - 825
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
IS - 12
ER -